Saturday 17 October 2026 Export CTEV’s income statement to Excel — free account

Claritev Corporation

CTEV Healthcare Health Information Services

Claritev Corporation’s revenue for fiscal 2025 (year ended December 2025) was $965.4 million, up 3.74% from fiscal 2024. In the quarter to June 2026, revenue grew 6.59%, EPS grew 8.40%, free cash flow grew 49.1% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

22.12 1.74 −7.29%

Follow CTEV

Alert me

Market cap: $404.4M
P/E: 0.0×
Fwd P/E: −1.6×
Dividend yield: —
F-score: 5/9
Altman Z: −0.40
Beneish M: −2.59
Dividend safety: n/a

Overview Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 2.33

Total sells 73.92

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	4	—	—	2	3	—	3	1	—	1	—	—
Sell	1	—	—	—	—	—	—	—	—	2	1	—

Insider Ownership 48.84%

Capital & Financial Ratios $m

Market Cap 404.36

Revenue 994.67

Net Income (283.11)

Free Cash Flow (17.92)

Net Debt 4,645.18

Current Ratio 1.00

Debt/Equity (16.23)

P/E ratio 0.00

Fwd P/E (1.62)

P/S ratio 0.38

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 12.62%

Next Y EPS Growth 10.51%

Next Y revenue growth 5.03%

Next 5Y EPS Growth 11.90%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 18.49%

10-year low 10-year high

EV/Sales against its own 10 years 22.54%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	81	30	28	28
Receivables	77	90	128	131
Inventory	—	—	—	—
Other	12	36	36	46
	194	176	224	236

	2023	2024	2025	Q'26
Payables	20	86	60	57
ST’ Debt	13	13	15	15
Other	—	—	—	—
	167	214	261	238

Compound Annual Growth %

	10y	5y	3y
Sales	—	0.58%	(3.66%)
Cash Flow	—	(20.84%)	(31.95%)
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	245	257	—	—	—
’25	231	242	246	247	965
’24	235	233	230	232	931
’23	237	238	243	244	962
’22	298	290	250	241	1,080
’21	255	276	288	298	1,118
’20	252	207	224	255	938

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(46)	93	—	—	—
’25	(30)	61	20	66	117
’24	50	18	73	(33)	108
’23	64	8	72	28	172
’22	195	41	109	28	372
’21	171	33	167	33	405
’20	147	44	140	45	377

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(93)	55	—	—	—
’25	(69)	37	(16)	36	(12)
’24	19	(7)	41	(64)	(11)
’23	41	(24)	50	(4)	63
’22	170	22	88	2	283
’21	153	15	147	6	320
’20	130	27	126	24	307

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(4.41)	(3.49)	—	—	—
’25	(4.38)	(3.81)	(4.23)	(4.88)	(17.30)
’24	(33.20)	(35.60)	(24.25)	(8.49)	(101.92)
’23	0.01	(2.40)	(1.60)	(2.00)	(5.60)
’22	2.80	0.80	1.20	(40.80)	(36.00)
’21	2.80	(2.80)	4.80	1.60	6.40
’20	(0.25)	(5.41)	(27.75)	(10.80)	(44.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	244.80	139.20	42.80	24.40	4.80	11.43	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	517.20	387.60	247.60	91.60	58.40	74.07
People
People	Employees	—	—	—	—	2,000	2,400	2,500	2,800	2,700	3,000
	Revenue/emp, $m	—	—	0.00	0.00	0.47	0.47	0.43	0.34	0.34	0.32
Income, $m
Income, $m	Revenue	—	—	1,041	983	938	1,118	1,080	962	931	965
	Gross margin, %	—	—	85.64	84.78	66.02	84.32	81.10	75.51	74.27	73.75
	EBT	—	—	44	11	(547)	135	(561)	(107)	(1,771)	(373)
	EBT margin, %	—	—	4.26	1.07	(58.32)	12.12	(51.93)	(11.13)	(190.27)	(38.64)
	Net income	—	0	36	10	(521)	102	(573)	(92)	(1,646)	(284)
	Depreciation	—	—	386	399	404	424	426	436	447	454
Per share, $
Per share, $	Revenue	—	—	100.16	94.58	79.68	68.67	67.60	59.62	57.63	58.74
	Earnings	—	—	3.49	0.93	(44.80)	6.40	(36.00)	(5.60)	(101.92)	(17.30)
	Cash flow	—	—	28.13	27.36	32.06	24.87	23.31	10.65	6.66	7.14
	Capex	—	—	(6.12)	(6.39)	(6.02)	(5.20)	(5.62)	(6.75)	(7.32)	(7.89)
	Free cash flow	—	—	22.01	20.97	26.05	19.67	17.69	3.90	(0.65)	(0.75)
	Book value	—	—	0.00	191.02	217.33	144.06	112.10	105.97	5.20	(10.17)
	Shares, m	—	—	10	10	12	16	16	16	16	16
Valuation, ×
Valuation, ×	P/E	—	—	972.00	972.00	0.00	27.69	0.00	0.00	0.00	0.00
	P/S	—	—	0.00	0.00	4.01	2.58	0.62	0.92	0.26	0.73
	P/B	—	—	3.78	3.78	1.47	1.23	0.37	0.52	2.84	0.00
	EV/Sales	—	—	0.00	0.00	8.77	6.79	4.70	5.56	5.08	5.46
	EV/FCF	—	—	0.00	0.00	26.81	23.71	17.97	85.07	(450.36)	(429.21)
Cash, $m
Cash, $m	Operating cash flow	—	—	292	284	377	405	372	172	108	117
	Capex	—	—	(64)	(66)	(71)	(85)	(90)	(109)	(118)	(130)
	Free cash flow	—	—	229	218	307	320	283	63	(11)	(12)
Balance, $m
Balance, $m	Working capital	—	—	—	30	96	177	271	27	(38)	(37)
	Total debt	—	—	—	5,407	4,585	4,892	4,755	4,546	4,523	4,595
	Net debt	—	—	—	5,385	4,459	4,704	4,415	4,464	4,493	4,567
	Shareholders’ equity	—	—	—	1,985	2,558	2,345	1,791	1,709	84	(167)
Returns, %
Returns, %	ROA	—	—	0.00	0.23	(6.26)	1.24	(7.35)	(1.28)	(27.17)	(5.66)
	ROIC	—	—	0.00	3.12	(1.17)	3.42	(3.65)	1.64	(18.98)	0.41
	ROE	—	—	0.00	0.43	(22.92)	4.16	(27.71)	(5.24)	(183.57)	683.76

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PHR Phreesia, Inc.	$685.3M	64.4×	23.5×	+10.41% (above 0%: growing)	+200.00% (above 0%: growing)	+43.51% (above 0%: growing)	66.64%	5.88%	Compare
MDRX Veradigm Inc.	$654.5M	— (loss-making)	— (loss-making)	−9.74% (below 0%: shrinking)	n/m	−66.33% (below 0%: shrinking)	50.53%	(37.41%)	Compare
SOPH SOPHiA GENETICS SA	$620.6M	— (loss-making)	— (loss-making)	+27.22% (above 0%: growing)	n/m	+6.50% (above 0%: growing)	64.61%	(86.03%)	Compare
WEAV Weave Communications, Inc.	$594.5M	— (loss-making)	— (loss-making)	+15.52% (above 0%: growing)	n/m	+94.33% (above 0%: growing)	72.03%	(6.49%)	Compare
EVH Evolent Health, Inc	$550.6M	— (loss-making)	— (loss-making)	+46.86% (above 0%: growing)	n/m	+58.67% (above 0%: growing)	12.39%	(1.47%)	Compare
NRC National Research Corporation	$466.9M	80.6×	4.9×	+3.98% (above 0%: growing)	n/m	+101.49% (above 0%: growing)	61.67%	(9.15%)	Compare
CTEV Claritev Corporation	$404.4M	— (loss-making)	— (loss-making)	+6.59% (above 0%: growing)	n/m	+49.10% (above 0%: growing)	73.72%	9.09%
CARL Carlsmed, Inc.	$380.9M	— (loss-making)	— (loss-making)	+56.75% (above 0%: growing)	n/m	−6.84% (below 0%: shrinking)	76.78%	(58.27%)	Compare
CSLT Castlight Health, inc.	$332.4M	— (loss-making)	— (loss-making)	−0.86% (below 0%: shrinking)	n/m	+106.49% (above 0%: growing)	66.20%	(5.42%)	Compare
Median of peers	$572.6M	—	—	+12.97%	—	+51.09%	65.41%	(7.82%)

All 51 Health Information Services stocks →

Claritev Corporation (CTEV) key facts

Strength: Claritev Corporation’s revenue for fiscal 2025 (year ended December 2025) was $965.4 million, up 3.74% from fiscal 2024.
Claritev Corporation (CTEV) is a Health Information Services company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, CTEV traded at $22.12, a market capitalization of $404.4 million.
Return on equity was 683.8% and debt-to-equity -16.23.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −0.40 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.